Michigan Center for Translational Pathology, Department of Pathology,University of Michigan Medical School, Ann Arbor, MI 48104-5054, USA.
Am J Clin Pathol. 2013 Jun;139(6):771-9. doi: 10.1309/AJCPN4L1BMRQPEIT.
Ewing family tumors (EFTs) and prostate carcinomas are characterized by rearrangement of ETS genes, most commonly FLI1 (EFTs) and ERG (prostate carcinomas). Previously, we characterized an antibody against ERG (EPR3864) for detecting ERG-rearranged prostate carcinoma. Because EPR3864 also cross-reacts with FLI1, we evaluated the usefulness of EPR3864 for discriminating EFTs from other small round blue cell tumors (SRBCTs) with immunohistochemistry. Of 57 evaluable EFTs, 47 (82%) demonstrated at least moderate, diffuse, nuclear ERG/FLI1 staining (including 89% and 100% of cases with confirmed EWSR1:FLI1 and EWSR1:ERG fusions, respectively), of which 1, 3, and 43 showed negative, cytoplasmic, or membranous CD99 staining, respectively. Among other SRBCTs (61 cases, 7 types), at least moderate, diffuse, nuclear EPR3864 staining was seen in all precursor B-lymphoblastic lymphomas/leukemias and subsets of Burkitt lymphomas (10%) and synovial sarcomas (45%). In summary, EPR3864 may be useful in detecting EWSR1:FLI1 and EWSR1:ERG rearranged EFTs in addition to prostate carcinomas.
尤文家族肿瘤 (EFTs) 和前列腺癌的特征是 ETS 基因重排，最常见的是 FLI1（EFTs）和 ERG（前列腺癌）。以前，我们鉴定了一种针对 ERG（EPR3864）的抗体，用于检测 ERG 重排的前列腺癌。由于 EPR3864 也与 FLI1 发生交叉反应，因此我们通过免疫组织化学评估了 EPR3864 用于区分 EFTs 和其他小圆蓝细胞肿瘤 (SRBCTs) 的有用性。在 57 例可评估的 EFTs 中，47 例（82%）至少表现出中度、弥漫性、核 ERG/FLI1 染色（包括分别确认的 EWSR1:FLI1 和 EWSR1:ERG 融合的 89%和 100%），其中 1、3 和 43 例分别显示阴性、细胞质或膜性 CD99 染色。在其他 SRBCTs（61 例，7 种）中，所有前体 B 淋巴细胞性淋母细胞/白血病和部分 Burkitt 淋巴瘤（10%）和滑膜肉瘤（45%）均可见至少中度、弥漫性、核 EPR3864 染色。总之，EPR3864 可能有助于检测除前列腺癌以外的 EWSR1:FLI1 和 EWSR1:ERG 重排的 EFTs。
